Amylin Receptor Agonist

Eloralintide (LY-3841136) is an amylin receptor agonist with human AMY1R EC₅₀ 23.9 pM and human AMY3R EC₅₀ 253.8 pM. Eloralintide induces decreased appetite, reduced food intake, body weight and fat mass loss, prolonged plasma calcium²⁺ reduction, and weak conditioned taste avoidance. Eloralintide can be used for the research of obesity.

CTR/AMYR modulator-2 is a dual agonist of human amylin receptor 3 (AMY3R) and calcitonin receptor (CTR). CTR/AMYR modulator-2 activates AMY3R and CTR, stimulating Rel EC₅₀ of cAMP production in UMUC3 cells by 4 nM and 1 nM, respectively. CTR/AMYR modulator-2 may be used in research on type 2 diabetes and obesity.

KBP-089 is a dual Amylin and Calcitonin Receptor agonist. KBP-089 reduces body weight, decreases adipose tissue mass and improves glucose tolerance in obese rats. KBP-089 also eliminates lipid accumulation in the liver and muscle, and ameliorates glycemic homeostasis and insulin sensitivity. KBP-089 is applicable to the research of diseases such as obesity and type 2 diabetes.

AMYR/CTR agonist 1 is an amylin receptor (AMYR) and calcitonin receptor (CTR) agonist with an amylin receptor cAMP stimulation EC₅₀ of 0.0995 nM and a calcitonin receptor cAMP stimulation EC₅₀ of 0.00616 nM. AMYR/CTR agonist 1 can be used for the research of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, insulin dependent diabetes, non-insulin dependent diabetes, impaired glucose tolerance, obesity, syndrome x.

Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide sodium may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases.

NN1213 acetate, a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with EC₅₀ values of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 acetate significantly reduces food intake and fat mass. NN1213 acetate can reduce body weightin diet-induced obese rats. NN1213 acetate can be used for the research of obesity.

Colulintide (LY3541105) is an amylin-calcitonin dual receptor agonist with Amylin as its scaffold. Colulintide is applicable to research related to type 2 diabetes and obesity.

Davalintide is an Amylin (HY-P1464)-mimetic peptide with greater potency and longer-lasting effects. Davalintide is a potent agonist of amylin receptor (IC₅₀ = 0.04 nM), calcitonin receptor (IC₅₀ = 0.06 nM) and calcitonin related peptide receptor (CGRP receptor) (IC₅₀ = 3.1 nM). Davalintide shows stronger potency to Amylin to activate cyclic AMP production through the calcitonin receptor (EC₅₀ = 1.4 nM). Davalintide regulates blood sugar and weight through various mechanisms such as delaying gastric emptying, inhibiting glucagon secretion, and reducing food intake. Davalintide can be used for the studies of anti-obesity and anti-diabetes.

Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases.

rel-CTR/AMYR agonist-1 is an agonist of amylin and/or calcitonin receptor. rel-CTR/AMYR agonist-1 can be used in research on metabolic diseases such as type 2 diabetes and obesity.

San45 is a nonselective dual amylin and calcitonin receptor agonist (DACRA) with nonselective potency relative to calcitonin receptor (CTR) and amylin 1 receptor (AMY₁R), and acts as a stabilizer of receptor-ligand complex and prolonged activator of cAMP signaling. San45 carries a conjugated lipid modification that can be used for the research of obesity.

Lenbelintide is a dual amylin/calcitonin receptor agonist. Lenbelintide can be studied in research on obesity.

TPM004 is an ultralong-acting, nonaggregating dual amylin (AMY3R) and calcitonin receptor (CTR) agonist with EC₅₀ values of 0.5 and 0.7 pM. TPM004 induces weight loss, attenuates adiposity rebound, lowers glucose, and improves glucose homeostasis. TPM004 can be used for the research of obesity, diabetes.

Batelintide is a dual amylin/calcitonin receptor agonist with antidiabetic effects.

KBP-066A is a long-acting dual amylin and calcitonin receptor agonist. KBP-066A can activate the CTR and AMY-R potently, with no off-target activity. KBP-066A reduces fasting blood glucose levels, fasting insulin levels, and body weight in diabetic rat models. KBP-066A can be used for the research of type 2 diabetes mellitus, obesity.

UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity.

NN1213, a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with EC₅₀ values of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 significantly reduces food intake and fat mass. NN1213 can reduce body weightin diet-induced obese rats. NN1213 can be used for the research of obesity.

BGM1812 is a dual agonist of amylin (hAMY3R) (EC₅₀ = 0.627 nM) and CGRP Receptor (hCTR) (EC₅₀ = 2.27 nM). BGM1812 achieves weight loss, increases the proportion of lean body mass, and reduces fat mass in diet-induced obese (DIO) rats. BGM1812 is applicable to research related to obesity.

Amylin agonist 1 is an agonist of amylin receptor 3 (AMY3R), with an EC₅₀ of 6.17 nM for stimulating cellular cAMP production. Amylin agonist 1 is also an agonist of calcitonin receptor (CTR), with an EC₅₀ of 8.58 nM. Amylin agonist 1 can be used for the research of type 2 diabetes and obesity.

KBP-336 is a dual amylin and calcitonin receptor agonist (DACRA). KBP-336 exhibits antidiabetic and insulin-sensitizing properties, improves glucose levels, spatial learning, and memory in diabetic rats, and reduces blood glucose. KBP-336 also alleviates pain-like symptoms in osteoarthritis rats. KBP-336 also promotes weight and fat reduction. KBP-336 is useful for research on diabetes, obesity, and arthritis.